Can-Fite BioPharma Ltd. (NYSE:CANF) Q3 2020 Earnings Conference Call November 30, 2020 9:15 AM ET Company Participants Paul Hoops - Investor Relations Pnina Fishman - Chief Executive Officer Motti Farbstein - Chief Financial Officer Conference Call Participants Peter Levine - Ameriprise Operator Greetings, and welcome to the Can-Fite BioPharma Third Quarter Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow t ...

Company Overview - Can-Fite is a clinical-stage drug development company focusing on small molecule drug products in Phase II and Phase III clinical studies[3] - The company has secured corporate partnerships and licensing deals, receiving approximately $18 million to date[3, 7] - Can-Fite's platform technology mimics the body's natural mechanisms to combat cancer and inflammation, targeting the A3 adenosine receptor (A3AR)[4] Drug Development Pipeline - **Piclidenoson:** - Rheumatoid Arthritis: Phase III study with 50% enrollment completed; interim analysis expected in Q4 2020; targets a market estimated at $50.5 billion by 2025[6, 10, 33] - Psoriasis: Phase III study with 50% enrollment completed; interim analysis expected in Q4 2020; addresses a market projected at $11.5 billion by the end of 2020[6, 14, 33] - COVID-19: Filed IND with the FDA for a Phase II study[6, 16] - **Namodenoson:** - Liver Cancer: Phase III study under preparation; targets a market estimated at $3.8 billion in 2027[6, 20, 33] - NASH: Phase II study achieved primary and secondary endpoints; aims for a market valued at $35 billion to $40 billion by 2025[6, 22, 33] - **CF602:** - Erectile Dysfunction: Ongoing development; targets a market estimated at $3.2 billion by 2022[6] - **Cannabinoid-Based Pharmaceuticals:** - Targeting autoimmune, cancer, and metabolic indications through collaboration; addresses a market projected to grow to $56.7 billion by 2026[6, 30, 31] Namodenoson NASH Phase II Study Results - All NASH cases were resolved in patients treated with 25 mg Namodenoson, compared to new NASH that developed in 5% of the placebo group (p<0.009)[28] - Patients treated with 25 mg of Namodenoson had a statistically significant reduction in hepatic fibrosis as measured by the Fibrosis-4 (FIB-4) score, as compared to placebo[25] - In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5% to 13.3% of the population, as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased from 37.5% to 35.3% of the population, with p=0.08[26]

Can-Fite BioPharma Ltd. (NYSE:CANF) Q2 2020 Earnings Conference Call August 27, 2020 4:15 PM ET Company Participants Pnina Fishman - Chief Executive Officer Motti Farbstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright & Co., LLC Operator Good afternoon, everyone, and thank you for joining Can-Fite's Second Quarter 2020 Conference Call. Today, the Company will provide a financial update for the quarter ended June 30, 2020, as well as ...

Can-Fite Presentation June 2020 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement • This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". • Forward-look ...

Can-Fite BioPharma Ltd. (NYSE:CANF) Q1 2020 Results Conference Call June 1, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Pnina Fishman - CEO Motti Farbstein - CFO Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Operator Greetings and welcome to the Can-Fite BioPharma First Quarter 2020 Business Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presenta ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 00 ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 00 ...

Can-Fite Presentation Pnina Fishman, CEO Motti Farbstein, CFO November 2018 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement • This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are ...